
1642

#4

TECH CENTER 1600/2900

		ILOH OLIVIER 1000/2300		
	TRANSPITAL LETTER		Case No. 10466/125	
Serial No.	E BION DE NE	Examiner	Group Art Unit	
09/944,403	August 30, 2001	To be assigned	1642	
Inventor(s)	ı			
Ashkenazi et al.				
Title of Invention	ISMEMBRANE POLYPEPTIDES AND N	ILICI FIC ACIDS ENCODI	NG THE SAME	
SECRETED AND TRAIN	ISMENIBRANE FOLTPEPTIBES AND IN	002210710120 2.1000.		

SECRET	ED AND-TRANSA	MEMBRANE	POLYPEPTIDES A	AND NUCLEIC AC	IDS ENCODING	G THE SAM	Ξ		
TO THE COMMISSIONER FOR PATENTS									
Transmitted herewith is <u>an Information Disclosure Statement; Form PTO-1449; 2 cited references; Statement regarding Relevant Priority Documents and return postcard.</u>									
	Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted.								
	A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.								
	Petition for amonth extension of time.								
\boxtimes	No additional fee is required.								
	The fee has bee	n calculated	as shown below:					0.1	
	_				Small	Entity	1	Other Small	
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Add'l Fee	or	Rate	Add'l Fee
Total		Minus			x \$9=		ļ	x \$18=	
Indep.		Minus			x 42=		ł	x \$84=_	
First Pres	sentation of Multip	ole Dep. Clai	<u>m</u>		+\$140=			+ \$280=	
	·		•		Total add'l fee	\$		Total add'l fee	\$
	Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$ A duplicate copy of this sheet is enclosed.								
	A check in the amount of \$ to cover the filing fee is enclosed.								
\boxtimes	The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.								
I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.									
				Respectfully s	ubmitted,	•			
Mmh.									
				Gregory M. Zin Registration N Agent for App	lo. 48,492				
P.O. BO	SO, ILLINOIS 606			3					
first class n	nail, with sufficient posts n, D.C. 20231, on 4	dence is being d age, in an envelo	eposited with the United S ope addressed to: Commi	States Postal Service as sssioner for Patents,					



MAY 0 3 2002 TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope, with sufficient postage, addressed to: Commissioner for Patents, Washington, D.C. 20231, on

Date of Deposit

Gregory M. Zinkl, Ph.D.

Name of Applicant, Assignee or Registered Representative

Signature

Date of Signature

Our Case No.: 10466/125

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: To be assigned

Group Art Unit No.: 1642

In re Application of:

Ashkenazi et al.

Serial No.: 09/944,403

Filing Date: August 30, 2001

For:

SECRETED AND

TRANSMEMBRANE

POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed below and on the attached Form PTO-1449 be considered by the Examiner and

made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

The references now cited are the following:

OTHER ART

- 1. Blast Results A1-A23, GenBank
- 2. Blast Results, B1-B9, Dayhoff

In accordance with 37 C.F.R. § 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement is being filed prior to the receipt of the first Official Action reflecting an examination on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these material, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed.

Applicant(s) respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

Gregory M. Zinkl, Ph.D. Registration No. 48,492

Agent for Applicant(s)

BRINKS HOFER GILSON & LIONE P.O. Box 10395 Chicago, IL 60610 (312) 321-4200 I hereby certify that this correspond to state deposited with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to:

Commissioner for Patents
Washington, D.C. 20231
on
Date of Deposit

Gregory M. Zinkl, Ph.D.

Name of applicant, assignee or Registered Representative

Signature

Signature

RECEIVED

MAY 0 3 2002

TECH CENTER 1600/2900

Our Case No. 10466/125

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Ashkenazi et al.)
Serial No. 09/944,403) Examiner To be assigned
Filing Date: August 30, 2001) Group Art Unit No. 1642
For SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME)))

RELEVANT PRIORITY DOCUMENTS

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

The following priority documents are relevant to the presently claimed invention:

1. 60/069694;

filed 12/16/1997

2. 60/074086;

filed 2/9/1998

3. PCT/US98/25108; filed 12/1/1998

4. 60/112850;

filed 12/16/1998

5. 09/216021;

filed 12/16/1998

6. 60/113296;

filed 12/22/1998

7. 09/218517;

filed 12/22/1998

8. 09/254311;

filed 3/3/1999

9. PCT/US99/28409; filed 11/30/1999

10. PCT/US99/28301; filed 12/1/1999

11. PCT/US99/30095; filed 12/16/1999

12. PCT/US00/05841; filed 3/2/2000

13. 09/866028;

filed 5/25/2001

Respectfully submitted,

Grégory M. Zinkl, Ph.D Registration No. 48,492

Agent for Applicant

BRINKS HOFER GILSON & LIONE P.O. BOX 10395 CHICAGO, ILLINOIS 60610 (312) 321-4200